Find Faculty
Max W Sung, MD
img_Max W Sung
PROFESSOR | Medicine, Hematology and Medical Oncology
Are you a patient?
View my
Provider Profile
Specialties
Internal Medicine, Cancer (Oncology), Hematology-Oncology

Dr. Sung is currently conducting clinical trials of immunotherapy in patients with advanced colorectal and breast cancers using gene transfer therapy. He is also involved in clinical trials of suicide gene therapy and differentiation therapies for colorectal cancer, and anti-angiogenesis therapy for hepatocellular carcinoma.

Dr. Sung actively participates in multi-modality treatment approaches (surgery/radiation/chemotherapy) to cancers of the liver, colon-rectum, carcinoid, pancreas, esophagus, stomach and anal cancers, and is also experienced in regional treatment modalities such as hepatic arterial chemotherapy/chemoembolization and intraperitoneal chemotherapy.

MD, Yeshiva University Albert Einstein College of Medicine

Internship, Internal Medicine, Montefiore Medical Center

Residency, Internal Medicine, Montefiore Medical Center

Fellowship, Hematology, Montefiore Medical Center

Certifications

American Board of Internal Medicine
58
Publications

Selected Publications

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Arvind Dasari, Erika P. Hamilton, Gerald S. Falchook, Judy S. Wang, Daneng Li, Max W. Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Scott Paulson. Investigational New Drugs

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Philipp K. Haber, Florian Castet, Miguel Torres-Martin, Carmen Andreu-Oller, Marc Puigvehí, Maeda Miho, Pompilia Radu, Jean Francois Dufour, Chris Verslype, Carolin Zimpel, Jens U. Marquardt, Peter R. Galle, Arndt Vogel, Melanie Bathon, Tim Meyer, Ismail Labgaa, Antonia Digklia, Lewis R. Roberts, Mohamed A. Mohamed Ali, Beatriz Mínguez, Davide Citterio, Vincenzo Mazzaferro, Fabian Finkelmeier, Jörg Trojan, Burcin Özdirik, Tobias Müller, Moritz Schmelzle, Anthony Bejjani, Max W. Sung, Myron E. Schwartz, Richard S. Finn, Swan Thung, Augusto Villanueva, Daniela Sia, Josep M. Llovet. Gastroenterology

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. Brett Marinelli, Edward Kim, Antonio D'Alessio, Mario Cedillo, Ishan Sinha, Neha Debnath, Masatoshi Kudo, Naoshi Nishida, Anwaar Saeed, Hannah Hildebrand, Ahmed O. Kaseb, Yehia I. Abugabal, Anjana Pillai, Yi Hsiang Huang, Uqba Khan, Mahvish Muzaffar, Abdul Rafeh Naqash, Rahul Patel, Aaron Fischman, Vivian Bishay, Dominik Bettinger, Max Sung, Celina Ang, Myron Schwartz, David J. Pinato, Thomas Marron. Journal for ImmunoTherapy of Cancer

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Sung during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • AstraZeneca AB

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.